The purpose this study is determine whether postoperative oral dosage of suzetrigine is effective at controlling postoperative pain and reducing analgesic requirements following primary total knee arthroplasty (TKA) versus a control group of TKA patients receiving postoperative Oxycodone.
The purpose of this prospective, randomized study is to compare the outcomes of two cohorts of patients undergoing primary total knee arthroplasty (TKA) and to determine whether postoperative administration of oral dosage of suzetrigine is effective at reducing postoperative pain versus a control group of patients receiving oral dosage of oxycodone only following primary total knee arthroplasty. The primary objective will be to compare the amount of postoperative narcotics utilized and postoperative VAS pain levels. The secondary objective will be to compare variables of patient functionality and other patient-reported outcome measures. The main questions it aims to answer are: 1. What is the efficacy of oral suzetrigine in reducing opioid consumption and postoperative pain following primary total knee arthroplasty? 2. Will the study results demonstrate the effectiveness and safety of oral suzetrigine after primary total knee arthroplasty in reducing postoperative opioid usage while maintaining a similar or better level of pain control when compared to a standard pain control regimen? Researchers will compare suzetrigine to a standard postoperative pain control regimen (Oxycodone) to see if suzetrigine is equivalent or more effective at reducing opioid consumption and postoperative pain following primary total knee arthroplasty. Participants will: * be randomized into one of two groups * undergo a primary TKA * complete a tracking sheet documenting daily pain medicine usage and VAS pain level for the first 14 days following the TKA * return to office at 2 weeks and 6 weeks postop for follow-up * complete additional questionnaires at 2 weeks and 6 weeks postop
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
140
patient receives a two-week supply of oral suzetrigine upon discharge
Patient will receive a two-week supply of oral Oxycodone upon discharge
Daily Opioid Use POD 1-14
Daily opioid use as measured in MME recorded daily for the first two weeks following TKA
Time frame: 2 weeks
total opioid usage over two weeks
total daily opioid usage (as measured in MME) for the first 14 days following TKA
Time frame: 2 weeks
Use of supplemental opioid POD 1-14
Average time from initial preop pain control dose to first postop supplemental opioid dose (for participants randomized to Group A, if applicable)
Time frame: 2 weeks
VAS pain score over two weeks
VAS (Visual Analogue Scale) pain score measuring highest level of knee pain experienced each day for the first 14 days following TKA. Scale 0-10
Time frame: 2 weeks
Opioid Usage at 6 weeks postop
Usage of opioids at 6 weeks postoperatively (Y/N) and if yes, what is daily usage
Time frame: 6 weeks
VAS Pain Score at 6 weeks
VAS (Visual Analogue Scale) pain score measuring highest level of knee pain at 6 weeks following TKA. Scale 0-10
Time frame: 6 weeks
KOOS, JR.
The Knee Injury and Osteoarthritis Outcome Score, Joint Replacement (KOOS, JR) is a survey measuring overall knee health for individuals post total knee arthroplasty (TKA) by evaluating stiffness, pain, function, and activities of daily living. Scoring scale 0-100.
Time frame: preoperatively and 6 weeks (± 2 weeks) postoperatively
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
ROM
active range-of-motion (ROM) as measured in degrees of extension and degrees of flexion
Time frame: preoperatively, 2 weeks and 6 weeks (± 2 weeks) postoperatively